CEO & Co-Founder of Gryphon Bio and Owl Therapeutics
BIOGRAPHY
June 25, 2025 Time: 8:00 AM PT, 11:00 AM ET
From Blind Spot to Biomarker: Transforming Brain Health Monitoring with ImmunoPCR
Speakers
-
Aleksandra Hemm
Product Manager, Thermo Fisher ScientificBIOGRAPHY
Event Date & Time
Date: June 25, 2025
Time: 8:00 AM PT, 11:00 AM ET
Abstract
Traumatic brain injury, together with adjacent brain conditions such as Alzheimer’s disease, is a global health crisis. In this presentation, Aleksandra Hemm, Product Manager from Thermo Fisher Scientific, introduces high-sensitivity immunoassay, including ImmunoPCR solutions for the detection of low-abundance protein biomarkers involved in neurological disorders, such as Neurofilament Light (NF-L), Tau, and TNFα. Dr. William Haskins, CEO & Co-Founder of Gryphon Bio and Owl Therapeutics™, describes a proteomic workflow for the discovery of brain biomarkers and progress in the development of proprietary ImmunoPCR reagents for blood tests for monitoring brain health. Gryphon’s advanced workflow has been successfully powered by Thermo Fisher Scientific’s high sensitivity ImmunoPCR solutions for:
- Proximity extension assay-based proteomic discovery of blood biomarkers with the Olink™ platform
- Proximity ligation assay-based clinical assay development with the Invitrogen™ ProQuantum™ platform
These complementary ImmunoPCR-based technologies, incorporating PCR amplification of oligonucleotide-labeled antibodies that bind protein biomarker targets, offer several benefits for brain biomarker measurements in various biofluids.
Gryphon’s focus is on transforming brain health with highly scalable and cost-effective technologies for longitudinal monitoring of novel biomarkers, from brain cells susceptible to aging, infection, injury, and disease. For 1), Gryphon has partnered with Owl Therapeutics to harness the Olink™ platform to discover distinct “waves” of elevated levels of novel brain biomarkers, as well as therapeutic targets, in biofluid samples from traumatic brain injury, mild cognitive impairment, and Alzheimer’s disease patients. For 2), Gryphon is now partnering with Thermo Fisher Scientific to develop clinical assays for a differentiated panel of brain biomarkers with the ProQuantum™ platform and to verify these findings in blood samples from large historical cohorts of patients.
Learning Objectives
- Gain insights into Gryphon’s process for transitioning from liquid chromatography-tandem mass spectrometry-based workflows to ImmunoPCR-based workflows for brain biomarkers
- Explore overlaps in brain biomarkers among adjacent brain conditions
- Discover how Thermo Fisher Scientific ’s Olink™ and Invitrogen™ ProQuantum™ platforms are accelerating Gryphon’s development of proprietary Immuno-PCR reagents for blood tests for monitoring brain health
Learn more about ELISA, ProQuantum and Multiplex Immunoassays for Neurobiology here >>
© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
You May Also Like
OCT 27, 2025 | 1:00 PM
C.E. CREDITS
Learn best practices for monitoring unfractionated heparin with aPTT, validating therapeutic ranges, and ensuring safe, effective anticoagulation....
OCT 28, 2025 | 7:00 AM
C.E. CREDITS
In recognition of Breast Cancer Awareness Month, join us for a live webinar to uncover the complexity of tumor biology and the surprising resilience of normal tissue. This event will feature...
OCT 28, 2025 | 9:00 AM
This webinar explains how CAR-T cells transfected using Solupore® technology from Avectas and sorted using the CGX10 Cell Isolation System from Sony Biotechnology outperform unsorted cel...
OCT 29, 2025 7:00 AM PT
This presentation explores the scientific rationale, preclinical validation, and early clinical translation of STAR-LLD—a novel, continuous low-dose percutaneous lenalidomide delivery...
OCT 29, 2025 | 8:00 AM
In today’s rapidly evolving landscape of next-generation sequencing (NGS), researchers face mounting pressure to deliver high-quality data from increasingly diverse and challenging sam...
OCT 29, 2025 | 9:00 AM
C.E. CREDITS
Congenital cytomegalovirus (cCMV) is the most common infectious cause of birth defects and non-genetic hearing loss in the United States, yet it remains underdiagnosed due to the absence of...
Loading Comments...